Company

Main promoter of Laminar Pharma. Professor of Cell Biology at the University of the Balearic Islands (UIB). He has more than 20 years of successful experience as a scientist and researcher and has held senior research positions in the United States (New York, Kansas City and Charleston), Switzerland (Geneva) and Hungary (Szeged).

He is a private investor focused on the development of entrepreneurial projects with high growth potential in their early stages. He has a master’s in business administration from IESE Business School. He is the director of the Palladium Hotel Group and the Founding Partner of the company Aguaduna.com as well as Kei Cities. His interests include innovation, biotechnology, smart cities, tourism, sustainability and blockchain.

Law graduate and practising lawyer since 1986, he has held public administration posts as Councillor and Deputy Mayor of Palma City Council (1987-1996), Councillor for Health (1996-99) and Councillor for Education and Culture (2003-2007), Member of the Island Council and the Balearic Parliament (1999-2003), Member and Speaker of the Balearic Parliament (2007-2009) and member of the National Education Council and the Interterritorial Council of the National Health System. He is an advisor to various educational and health institutions, including the Medical Association of the Balearic Islands.

He holds a degree in Biological Sciences (UIB, 1985) and ornithology. His professional activities since 1987 focused on aquaculture and environmental conservation. He holds a master´s degree (with honours) in evaluation and correction of environmental impacts by the UCM and the UPM (1993-1995) and won the Ángel Ramos Award for the best project. In 1995 he founded the company Duna Baleares SL, the first environmental consultancy in the Pitiusas Islands.

She has worked in the financial department of Coflusa and Viajes Iberia S.A. for 15 years. She is a key investor in Laminar Pharma, of which she was also a director before becoming a consultant in 2006.

He was the Minister of Health and Consumer Affairs of Spain from July 2007 to April 2009.He has a PhD in Medicine from the University of Valencia and is a current Professor of Physiology at the University Miguel Hernández of Elche.  He was the coordinator of the Physiology area of the National Agency of Evaluation and Prospective (ANEP) between 1991 and 1994. He is the former coordinator of the European Embryonic Stem Cell Network and a former Professor of Physiology at the Pablo de Olavide University.

He also was the director of the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) and the executive director of the Progreso y Salud Foundation until 2019.

CFO since 2020, previously with Chief Financial Officer functions in international groups related to tourism enterprises, such as Thomas Cook Airlines, TUI/Hotelbeds Group or Riu Hotels. He has also worked as an auditor at KPMG. He holds a degree in Economics and Business Administration and is a Chartered Accountant awarded by the Official Register of Statutory Auditors. In 2021 he completed the Advanced General Management Program at Instituto de Empresa.

He has a degree in Economic, Political and Commercial Sciences, Business Economics section, Diploma in Operational Research and is a Chartered Accountant awarded by the Official Register of Statutory Auditors with more than 30 years of experience in account auditing, financial consulting, as well as a professor at the UNED.

Manfred Horst, MD, PhD, MBA is an experienced Business Developer who draws from more than 30 years of experience in the pharmaceutical and healthcare industries. Manfred studied medicine in Munich, Montpellier and London and is a board-certified specialist in Allergic Diseases and Immunology ; he also holds an MBA from INSEAD, Fontainebleau.  Before setting up his own healthcare consultancy in 2017, Manfred was a Business Development Executive for Merck Research Laboratories (Merck & Co.’s/ MSD’s Research & Development Division) and had been instrumental in a number of important deals between Merck and European/israeli biotech companies.

Degree in Economics and Business Sciences from the Comillas Pontifical University (ICADE) and in Political Sciences from UNED. She graduated in Pharmacy from the CEU Cardenal Herrera University. Master in Political CC from the College of Europe in Bruges (Belgium).
She has worked in the General Secretariat of the European Commission, and later in different institutional functions in Valencia. She is currently a community pharmacist, member of Deontology at the MICOF of Valencia and territorial delegate of COFARES in the region of Valencia and the Balearic Islands.

Ph.D. in Quantitative Finance from the University of the Basque Country and a degree in Economics from the University of Alicante. He is currently a professor at the Universitat de les Illes Balears and director of the Master’s Degree in Big Data Analysis for Economics and Business. His research focuses on financial econometrics, computational finance, and financial derivatives such as employee stock options. He has completed a postdoctoral stay at UCLA-Anderson School of Management (visiting scholar). He has participated as a teacher in master’s programs at the University of Navarra, Carlos III University of Madrid or the Universitat Oberta de Catalunya.

Degree in Environmental Sciences with Extraordinary Award and 5-star University Award. Master in administration and management of SMEs. Director of cableworld since 2007. Founding partner of Micre activities.

Degree in Biology and Biochemistry and PhD in Cell Biology by the UIB. Dr. Lladó has completed postdoctoral stays at prestigious international institutions such as the Gastrointestinal Unit of MGH Harvard Medical School (Boston, MA, USA) and the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and has enjoyed postdoctoral fellowships for the development of the Melitherapy from the Spanish Association Against Cancer, the Ministry of Science and Innovation (Torres Quevedo program) and the Marathon Foundation. She is the author of more than 20 scientific publications. Dr. Lladó joined Laminar Pharma in 2018 as Chief Scientific Officer and relocated to Boston (USA) in February 2021 for the direction of the company’s business, commercial and scientific strategy in the USA.

Paula graduated in Biochemistry from the University of Oviedo in 2012. That same year she joined Dr. Pablo V. Escribá’s team, first with a grant from the Marathon Foundation and later, through the company Laminar Pharmaceuticals, where she joined with a Torres Quevedo contract. During the first years she developed her research activity in the field of proteomics, molecular biology and the search for biomarkers applied to the study of the mechanism of action of 2OHOA, a molecule in an advanced state of development (clinical Phase III), in the area of ​​oncology. In recent years she focused her career on a more translational profile, getting involved in decision-making related to the clinical and strategic development of the company. She is currently the scientific director and has an active role in the company’s executive committee. In addition, she participates in several research projects, some as principal investigator, in the training of future scientists and in obtaining both public and private funding.

Dr. Rello holds a degree in Economics, Law, Business Administration and Management, and a PhD in Economics and Business Sciences and a PLD – Program for Leadership Development from Harvard Business School (Boston / USA).. He has more than 20 years of professional experience as CFO in the pharmaceutical and biotechnology sector, in listed companies such as Oryzon Genomics and subsidiaries of multinational groups such as Sandoz IP (Novartis). Professor of the Department of Economics and Business of the Universitat Abat Oliba and of the Master’s in Management of Biotech Companies of the Faculty of Pharmacy of the Universidad San Pablo. Among other positions, he holds the positions of Member of Consultative Working Group (CWG) – Corporate Finance Standing Committee (CFSC) ESMA – European Securities and Markets Authority and Member of the Board of Directors of Spanish Issuers.

Degree in Biology and Biochemistry and PhD in Cell Biology by the UIB. Dr. Lladó has completed postdoctoral stays at prestigious international institutions such as the Gastrointestinal Unit of MGH Harvard Medical School (Boston, MA, USA) and the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and has enjoyed postdoctoral fellowships for the development of the Melitherapy from the Spanish Association Against Cancer, the Ministry of Science and Innovation (Torres Quevedo program) and the Marathon Foundation. She is the author of more than 20 scientific publications. Dr. Lladó joined Laminar Pharma in 2018 as Chief Scientific Officer and relocated to Boston (USA) in February 2021 for the direction of the company’s business, commercial and scientific strategy in the USA.

Dr. Fernández holds a degree in Biochemistry (University of Oviedo) and a PhD in Biochemistry and Molecular Biology (University of Oviedo). After a brief period at the UIB, she joined Laminar Pharma in November 2013. During her time as a researcher, she focused mainly in the fields of proteomics and molecular biology participating in the elucidation of the mechanism of antitumor action of LAM561 and in the identification and development of biomarkers to support its clinical development. She currently leads both basic and applied research for the company.

Antonio González joined Laminar in 2010 and participated in the design and development of the project’s business model. He holds a diploma in Economic and Business Sciences and a bachelor’s degree in Business Administration and Management, and he is also a qualified technician in Foreign Trade. He has 25 years of previous experience in auditing and consulting, transportation and import-export.

CFO since 2020, previously with Chief Financial Officer functions in international groups related to tourism enterprises, such as Thomas Cook Airlines, TUI/Hotelbeds Group or Riu Hotels. He has also worked as an auditor at KPMG. He holds a degree in Economics and Business Administration and is a Chartered Accountant awarded by the Official Register of Statutory Auditors. In 2021 he completed the Advanced General Management Program at Instituto de Empresa.

Head of Chemistry Manufacturing and Controls at Laminar since 2020, where she joined as senior scientist in 2016. She holds a degree in Biology and a degree in Biochemistry from the University of the Balearic Islands, and a PhD in Molecular Biology from the Autonomous University of Madrid. With a background in developmental biology and cell division, she occupied research positions at Lund University (Sweden) and at the UIB (with a European FP7 Marie Curie grant). In 2019, she became head of the clinical R&D scientific area at Laminar and, the year after, Head of CMC. CMC department is responsible for all drug substance (API) and drug product (DP) activities from preclinical development through clinical supplies for Phase 3 registration studies (cGMP manufacture and supply chain of API and DP in support of ongoing clinical programs) together with identification, selection and management of Contract Manufacturing Organizations (CMOs) and collaboration in the writing and reviewing of documents for regulatory submissions.

Dr. McNicholl holds a PhD. in Medicine and Surgery; formerly a post-doctoral researcher at CIBERehd, he has participated in over 60 traslational research projects including the design and coordination of several clinical trials, producing over 40 indexed publications (H-index= 21). He founded in 2013 and has been the Scientific Director (until 2019) of the non-profit Spanish Platform for Collaborative Research in Gastroenterology (AEG‐REDCap) with more than 70 projects, and 1,600 researchers in 45 countries. He has coordinated several courses and books on evidence based clinical practice and traslational research, and received over 10 international awards and grants for his oral and poster presentations.